Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1964 1
1975 1
1976 1
1989 2
1990 1
1991 3
1992 11
1993 5
1994 7
1995 6
1996 3
1997 5
1998 5
1999 1
2000 2
2001 2
2002 7
2003 6
2004 7
2005 11
2006 9
2007 9
2008 10
2009 10
2010 18
2011 6
2012 4
2013 5
2014 8
2015 7
2016 8
2017 7
2018 8
2019 4
2020 3
2021 5
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators. Ravaud A, et al. N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9. N Engl J Med. 2016. PMID: 27718781 Free article. Clinical Trial.
Abdominal vascular catastrophes.
Eldrup-Jorgensen J, Hawkins RE, Bredenberg CE. Eldrup-Jorgensen J, et al. Among authors: hawkins re. Surg Clin North Am. 1997 Dec;77(6):1305-20. doi: 10.1016/s0039-6109(05)70619-8. Surg Clin North Am. 1997. PMID: 9431341 Review.
Discovery of antibodies.
Llewelyn MB, Hawkins RE, Russell SJ. Llewelyn MB, et al. Among authors: hawkins re. BMJ. 1992 Nov 21;305(6864):1269-72. doi: 10.1136/bmj.305.6864.1269. BMJ. 1992. PMID: 1477573 Free PMC article. Review.
Principles of antibody therapy.
Russell SJ, Llewelyn MB, Hawkins RE. Russell SJ, et al. Among authors: hawkins re. BMJ. 1992 Dec 5;305(6866):1424-9. doi: 10.1136/bmj.305.6866.1424. BMJ. 1992. PMID: 1486312 Free PMC article. Review.
Overcoming the toxicity hurdles of genetically targeted T cells.
Casucci M, Hawkins RE, Dotti G, Bondanza A. Casucci M, et al. Among authors: hawkins re. Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9. Cancer Immunol Immunother. 2015. PMID: 25488419 Free PMC article. Review.
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.
Kalaitsidou M, Moon OR, Sykorova M, Bao L, Qu Y, Sukumaran S, Valentine M, Zhou X, Pandey V, Foos K, Medvedev S, Powell DJ Jr, Udyavar A, Gschweng E, Rodriguez R, Dudley ME, Hawkins RE, Kueberuwa G, Bridgeman JS. Kalaitsidou M, et al. Among authors: hawkins re. Front Immunol. 2023 Nov 7;14:1256491. doi: 10.3389/fimmu.2023.1256491. eCollection 2023. Front Immunol. 2023. PMID: 38022678 Free PMC article.
198 results